Tesamorelin is a 44-amino-acid synthetic analogue of growth-hormone-releasing hormone (GHRH). A trans-3-hexenoic acid moiety extends its stability, prolonging interaction with the pituitary GHRH receptor and supporting endogenous GH release.
FDA-approved as Egrifta™ for HIV-associated lipodystrophy, Tesamorelin has been characterized in research for selective visceral-fat reduction while preserving lean mass.
- Visceral adipose tissue research with lean-mass preservation
- Insulin-sensitivity and lipid-profile studies
- Endogenous GH and IGF-1 axis investigation
- Sleep architecture and recovery research
- CAS
- 218949-48-5
- Formula
- C₂₂₁H₃₆₆N₇₂O₆₇S
Lyophilized vial stable at 2–8 °C; -20 °C for long-term storage. Reconstitute with sterile bacteriostatic water; reconstituted solution stable for up to 30 days at 2–8 °C.
For research and laboratory use only. Not for human or veterinary consumption.
How to run this compound.
Add bacteriostatic water to the sealed vial. Swirl — do not shake. Refrigerate after reconstitution.
Reconstitute with bacteriostatic water. Subcutaneous administration on protocol cadence.
Run on the protocol schedule. The system rewards consistency over intensity.
Pair with complementary REFRAME lines. See suggestions below.
